PHARMAC considering multiple new treatments from Takeda

PHARMAC

19 September 2022 - Pharmac has initiated consultation today on a provisional bundle deal with Takeda to fund vedolizumab for people with inflammatory bowel disease and brentuximab vedotin for people with relapsed or refractory Hodgkin's lymphoma.

If approved by PHARMAC, vedolizumab would be funded from 1 February 2023 for eligible people with ulcerative colitis or Crohn’s disease, which are forms of inflammatory bowel disease.

Read PHARMAC Consultation

Michael Wonder

Posted by:

Michael Wonder